Newer first-line option for advanced HCC.

Prepare for Liver Disease and Tumors Test with tailored flashcards and questions. Get detailed explanations and improve your knowledge. Ace the medical student exam!

Multiple Choice

Newer first-line option for advanced HCC.

In advanced hepatocellular carcinoma, the treatment approach has moved beyond single-agent TKIs to combinations that engage the immune system and block tumor blood vessel growth. The best first-line option is the combination of atezolizumab and bevacizumab because it has shown a clear survival advantage over the prior standard. This regimen pairs a PD-L1 inhibitor (atezolizumab) with an anti-VEGF antibody (bevacizumab). In the pivotal trial, patients receiving atezolizumab–bevacizumab lived longer overall and remained progression-free longer than those treated with sorafenib, with higher response rates and durable responses. The combination’s success is thought to come from synergy: bevacizumab can normalize tumor blood vessels and enhance immune cell access to the tumor, while atezolizumab unleashes anti-tumor immunity by blocking PD-L1. This translates into meaningful clinical benefit for eligible patients. However, it’s important to select patients carefully. The regimen is typically used in those with well-preserved liver function (often Child-Pugh A) and without contraindications to bevacizumab, such as significant bleeding risk from varices or recent major bleeding. If bevacizumab isn’t suitable or if immunotherapy is not feasible, other first-line options like lenvatinib exist, but they have not demonstrated the same combination survival advantage as this atezolizumab–bevacizumab pair. Regorafenib, by contrast, is used after progression on sorafenib, not as a first-line therapy.

In advanced hepatocellular carcinoma, the treatment approach has moved beyond single-agent TKIs to combinations that engage the immune system and block tumor blood vessel growth. The best first-line option is the combination of atezolizumab and bevacizumab because it has shown a clear survival advantage over the prior standard.

This regimen pairs a PD-L1 inhibitor (atezolizumab) with an anti-VEGF antibody (bevacizumab). In the pivotal trial, patients receiving atezolizumab–bevacizumab lived longer overall and remained progression-free longer than those treated with sorafenib, with higher response rates and durable responses. The combination’s success is thought to come from synergy: bevacizumab can normalize tumor blood vessels and enhance immune cell access to the tumor, while atezolizumab unleashes anti-tumor immunity by blocking PD-L1. This translates into meaningful clinical benefit for eligible patients.

However, it’s important to select patients carefully. The regimen is typically used in those with well-preserved liver function (often Child-Pugh A) and without contraindications to bevacizumab, such as significant bleeding risk from varices or recent major bleeding. If bevacizumab isn’t suitable or if immunotherapy is not feasible, other first-line options like lenvatinib exist, but they have not demonstrated the same combination survival advantage as this atezolizumab–bevacizumab pair. Regorafenib, by contrast, is used after progression on sorafenib, not as a first-line therapy.

More practice questions